Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
MuSK cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis
Marius Halliez, … , Rozen Le Panse, Laure Strochlic
Marius Halliez, … , Rozen Le Panse, Laure Strochlic
Published June 12, 2025
Citation Information: J Clin Invest. 2025;135(15):e173308. https://doi.org/10.1172/JCI173308.
View: Text | PDF
Research Article Immunology Muscle biology Neuroscience

MuSK cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis

  • Text
  • PDF
Abstract

The neuromuscular junction (NMJ), a synapse between the motor neuron terminal and a skeletal muscle fiber, is crucial throughout life in maintaining the reliable neurotransmission required for functional motricity. Disruption of this system leads to neuromuscular disorders, such as autoimmune myasthenia gravis (MG), the most common form of NMJ disease. MG is caused by autoantibodies directed mostly against the acetylcholine receptor (AChR) or the muscle-specific kinase MuSK. Several studies report immunoreactivity to the Frizzled-like cysteine-rich Wnt-binding domain of MuSK (CRD) in patients, although the pathogenicity of the antibodies involved remains unknown. We showed here that the immunoreactivity to MuSK CRD induced by the passive transfer of anti-MuSKCRD antibodies in mice led to typical MG symptoms, characterized by a loss of body weight and a locomotor deficit. The functional and morphological integrity of the NMJ was compromised with a progressive decay of neurotransmission and disruption of the structure of presynaptic and postsynaptic compartments. We found that anti-MuSKCRD antibodies completely abolished Agrin-mediated AChR clustering by decreasing the Lrp4-MuSK interaction. These results demonstrate the role of the MuSK CRD in MG pathogenesis and improve our understanding of the underlying pathophysiological mechanisms.

Authors

Marius Halliez, Steve Cottin, Axel You, Céline Buon, Antony Grondin, Léa S. Lippens, Mégane Lemaitre, Jérome Ezan, Charlotte Isch, Yann Rufin, Mireille Montcouquiol, Nathalie Sans, Bertrand Fontaine, Julien Messéant, Rozen Le Panse, Laure Strochlic

×

Figure 5

Molecular mechanisms of anti-MuSKCRD antibodies in vitro.

Options: View larger image (or click on image) Download as PowerPoint
Molecular mechanisms of anti-MuSKCRD antibodies in vitro.
(A) Western bl...
(A) Western blot of surface-biotinylated proteins (Biot) in C2C12 myotubes with (CRD) and without (Ctl) treatment with anti-MuSKCRD antibodies for 16 hours. Whole-lysate Western blots (Input) were performed to demonstrate the presence of the proteins of interest. Ctl, control; IB, immunoblot; TfR, transferrin receptor; GAPDH, loading control. (B) Quantitative analysis of A showing the ratio of biotinylated MuSK to TfR normalized relative to Ctl conditions. (C) MuSK-FLAG and Lrp4-HA co-IP assay with FLAG Fab-Trap agarose in transfected COS7 cells. Cells were left untreated (Ctl) or were subjected to pretreatment with anti-MuSKCRD antibodies (CRD) for 16 hours. (D) Quantitative analysis of C, corresponding to the ratio of IP Lrp4-HA to MuSK-FLAG normalized against the Ctl condition (lane 4 in C). (E) MuSK IP in C2C12 myotubes left untreated or treated with Agrin after 3 hours of pretreatment with anti-MuSKCRD antibodies (CRD). The 4G10 anti-phosphotyrosine antibody was used to assess MuSK phosphorylation. (F) Quantitative analysis of E corresponding to the 4G10 signal divided by the IP MuSK signal normalized against Ctl conditions (Ctl untreated [UT]). The data are shown as mean ± SEM. n = 4 (B and D) and n = 3 (F) independent experiments; ns, not significant; *P < 0.05; **P < 0.01; ****P < 0.0001; Mann-Whitney U test (B and D) or 2-way ANOVA with Tukey’s post hoc test (F).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts